Oral administration of ginger-derived nanolipids loaded with siRNA as a novel approach for efficient siRNA drug delivery to treat ulcerative colitis

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu. Rev. Immunol. 28, 573–621 (2010).
  Medline CASGoogle Scholar
• 2 Vavricka SR, Gubler M, Gantenbein C et al. Anti-TNF treatment for extraintestinal manifestations of inflammatory bowel disease in the swiss IBD cohort study. Inflamm. Bowel Dis. 23(7), 1174–1181 (2017).
  MedlineGoogle Scholar
• 3 Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91(4), 854–862 (2001).
  Medline CASGoogle Scholar
• 4 Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48(4), 526–535 (2001).
  Medline CASGoogle Scholar
• 5 Neurath MF. Current and emerging therapeutic targets for IBD. Nat. Rev. Gastroenterol. Hepatol. 14(5), 269–278 (2017).
  Medline CASGoogle Scholar
• 6 Sam JJ, Bernstein CN, Razik R, Thanabalan R, Nguyen GC. Physicians’ perceptions of risks and practices in venous thromboembolism prophylaxis in inflammatory bowel disease. Dig. Dis. Sci. 58(1), 46–52 (2013).
  Medline CASGoogle Scholar
• 7 Kumar J, Newton A. Colon targeted rifaximin nanosuspension for the treatment of inflammatory bowel disease (IBD). Antiinflamm. Antiallergy Agents Med. Chem. 15(2), 101–117 (2016).
  Medline CASGoogle Scholar
• 8 Razanskaite V, Bettey M, Downey L et al. Biosimilar infliximab in inflammatory bowel disease: outcomes of a managed switching programme. J. Crohns Colitis 11(6), 690–696 (2017).
  MedlineGoogle Scholar
• 9 Dong R, Zheng S, Chen G. The appropriate dose and cost of iron replacement therapy in patients with IBD. Gut 66(1), 196–197 (2017).
  MedlineGoogle Scholar
• 10 Ghosh S, Louis E, Beaugerie L et al. Development of the IBD disk: a visual self-administered tool for assessing disability in inflammatory bowel diseases. Inflamm. Bowel Dis. 23(3), 333–340 (2017).
  MedlineGoogle Scholar
• 11 Walker JR, Ediger JP, Graff LA et al. The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12 month anxiety and mood disorders. Am. J. Gastroenterol. 103(8), 1989–1997 (2008).
  MedlineGoogle Scholar
• 12 Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: results of the REFURBISH study. Am. J. Gastroenterol. 108(1), 99–105 (2013).
  Medline CASGoogle Scholar
• 13 Nielsen OH, Loftus EV Jr, Jess T. Safety of TNF-alpha inhibitors during IBD pregnancy: a systematic review. BMC Med. 11, 174 (2013).
  Medline CASGoogle Scholar
• 14 Fiorino G, Danese S, Pariente B, Allez M. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-alpha agents. Autoimmun. Rev. 13(1), 15–19 (2014).
  Medline CASGoogle Scholar
• 15 Laroui H, Geem D, Xiao B et al. Targeting intestinal inflammation with CD98 siRNA/PEI-loaded nanoparticles. Mol. Ther. 22(1), 69–80 (2014). • Describes a synthetic nanoparticle to delivery CD98 siRNA to decrease colitis.
  Medline CASGoogle Scholar
• 16 Maisel K, Ensign L, Reddy M, Cone R, Hanes J. Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse. J. Control. Release 197, 48–57 (2015).
  Medline CASGoogle Scholar
• 17 Zhang MZ, Xu CL, Wen LQ et al. A Hyaluronidase-responsive nanoparticle-based drug delivery system for targeting colon cancer cells. Cancer Res. 76(24), 7208–7218 (2016).
  Medline CASGoogle Scholar
• 18 Xiao B, Zhang Z, Viennois E et al. Combination therapy for ulcerative colitis: orally targeted nanoparticles prevent mucosal damage and relieve inflammation. Theranostics 6(12), 2250–2266 (2016).
  Medline CASGoogle Scholar
• 19 Zhang MZ, Yu Y, Yu RN, Wan M, Zhang RY, Zhao YD. Tracking the down-regulation of folate receptor-alpha in cancer cells through target specific delivery of quantum dots coupled with antisense oligonucleotide and targeted peptide. Small 9(24), 4183–4193 (2013).
  Medline CASGoogle Scholar
• 20 Zhang MZ, Li C, Fang BY et al. High transfection efficiency of quantum dot-antisense oligonucleotide nanoparticles in cancer cells through dual-receptor synergistic targeting. Nanotechnology 25(25), 255102 (2014).
  MedlineGoogle Scholar
• 21 Laroui H, Viennois E, Xiao B et al. Fab'-bearing siRNA TNF alpha-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis. J. Control. Release 186, 41–53 (2014).
  Medline CASGoogle Scholar
• 22 Huang Z, Gan JJ, Jia LX et al. An orally administrated nucleotide-delivery vehicle targeting colonic macrophages for the treatment of inflammatory bowel disease. Biomaterials 48, 26–36 (2015).
  Medline CASGoogle Scholar
• 23 Zhang M, Viennois E, Prasad M et al. Edible ginger-derived nanoparticles: a novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer. Biomaterials 101, 321–340 (2016).
  Medline CASGoogle Scholar
• 24 Zhang MZ, Collins JF, Merlin D. Do ginger-derived nanoparticles represent an attractive treatment strategy for inflammatory bowel diseases? Nanomedicine 11(23), 3035–3037 (2016).
  CASGoogle Scholar
• 25 Hang TTN, Dalmasso G, Torkvist L et al. CD98 expression modulates intestinal homeostasis, inflammation, and colitis-associated cancer in mice. J. Clin. Invest. 121(5), 1733–1747 (2011).
  MedlineGoogle Scholar
• 26 Rietbergen MM, Martens-De Kemp SR, Bloemena E et al. Cancer stem cell enrichment marker CD98: A prognostic factor for survival in patients with human papillomavirus-positive oropharyngeal cancer. Eur. J. Cancer 50(4), 765–773 (2014).
  Medline CASGoogle Scholar
• 27 Kucharzik T, Lugering A, Yan YT et al. Activation of epithelial CD98 glycoprotein perpetuates colonic inflammation. Lab. Invest. 85(7), 932–941 (2005).
  Medline CASGoogle Scholar
• 28 Sussman DA, Santaolalla R, Strobel S et al. Cancer in inflammatory bowel disease: lessons from animal models. Curr. Opin. Gastroen. 28(4), 327–333 (2012).
  Medline CASGoogle Scholar
• 29 Sun CC, Zargham R, Shao Q et al. Association of CD98, integrin beta 1, integrin beta 3 and Fak with the progression and liver metastases of colorectal cancer. Pathol. Res. Pract. 210(10), 668–674 (2014).
  Medline CASGoogle Scholar
• 30 Mu JY, Zhuang XY, Wang QL et al. Interspecies communication between plant and mouse gut host cells through edible plant derived exosome-like nanoparticles. Mol. Nutr. Food Res. 58(7), 1561–1573 (2014).
  Medline CASGoogle Scholar
• 31 Kansas state University. Kansas Lipidomics Research Center. www.k-state.edu/lipid/lipidomics/profiling.html.
  Google Scholar
• 32 Zhang MZ, Xiao B, Wang H et al. Edible ginger-derived nano-lipids loaded with doxorubicin as a novel drug-delivery approach for colon cancer therapy. Mol. Ther. 24(10), 1783–1796 (2016). •• Provides detailed information about how to prepare ginger-derived nanolipids for chemotherapy-doxorubicin delivery.
  Medline CASGoogle Scholar
• 33 Ju SW, Mu JY, Dokland T et al. Grape exosome-like nanoparticles induce intestinal stem cells and protect mice from DSS-induced colitis. Mol. Ther. 21(7), 1345–1357 (2013).
  Medline CASGoogle Scholar
• 34 Zhuang XY, Teng Y, Samykutty A et al. Grapefruit-derived nanovectors delivering therapeutic miR17 through an intranasal route inhibit brain tumor progression. Mol. Ther. 24(1), 96–105 (2016). • Describes an miRNA delivery system based on grapefruit-derived lipids.
  Medline CASGoogle Scholar
• 35 Yang JS, Gad H, Lee SY et al. A role for phosphatidic acid in COPI vesicle fission yields insights into Golgi maintenance. Nat. Cell Biol. 10(10), 1146–1153 (2008).
  Medline CASGoogle Scholar
• 36 Kooijman EE, Chupin V, de Kruijff B, Burger KNJ. Modulation of membrane curvature by phosphatidic acid and lysophosphatidic acid. Traffic 4(3), 162–174 (2003).
  Medline CASGoogle Scholar
• 37 Popova AV, Hincha DK. Effects of flavonol glycosides on liposome stability during freezing and drying. BBA Biomembranes 1858(12), 3050–3060 (2016).
  Medline CASGoogle Scholar
• 38 Tam YY, Chen S, Cullis PR. Advances in lipid nanoparticles for siRNA delivery. Pharmaceutics 5(3), 498–507 (2013). •• Gives a detailed description of current situation of lipid nanoparticles for siRNA delivery.
  Medline CASGoogle Scholar
• 39 Foged C. siRNA delivery with lipid-based systems: promises and pitfalls. Curr. Top. Med. Chem. 12(2), 97–107 (2012).
  Medline CASGoogle Scholar
• 40 Srinivas R, Samanta S, Chaudhuri A. Cationic amphiphiles: promising carriers of genetic materials in gene therapy. Chem. Soc. Rev. 38(12), 3326–3338 (2009).
  Medline CASGoogle Scholar
• 41 Zhang MZ, Viennois E, Xu CL, Merlin D. Plant derived edible nanoparticles as a new therapeutic approach against diseases. Tissue Barriers 4(2), e1134415 (2016).
  MedlineGoogle Scholar
• 42 Yang SY, Zheng Y, Chen JY et al. Comprehensive study of cationic liposomes composed of DC-Chol and cholesterol with different mole ratios for gene transfection. Colloid Surf. B 101, 6–13 (2013).
  Medline CASGoogle Scholar
• 43 Sato A, Takagi M, Shimamoto A et al. Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials 28(7), 1434–1442 (2007).
  Medline CASGoogle Scholar
• 44 Kawakami S, Yamashita F, Nishikawa M et al. Asialoglycoprotein receptor-mediated gene transfer using novel galactosylated cationic liposomes. Biochem. Bioph. Res. Commun. 252(1), 78–83 (1998).
  Medline CASGoogle Scholar
• 45 Desigaux L, Sainlos M, Lambert O et al. Self-assembled lamellar complexes of siRNA with lipidic aminoglycoside derivatives promote efficient siRNA delivery and interference. Proc. Natl Acad. Sci. USA 104(42), 16534–16539 (2007).
  Medline CASGoogle Scholar
• 46 Li LY, Hou JJ, Liu XJ et al. Nucleolin-targeting liposomes guided by aptamer AS1411 for the delivery of siRNA for the treatment of malignant melanomas. Biomaterials 35(12), 3840–3850 (2014).
  Medline CASGoogle Scholar
• 47 Xiao B, Laroui H, Viennois E et al. Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterology 146(5), 1289–1300 (2014). • Showed that regulated CD98 expression by CD98 siRNA was a reliable way to reduce colitis in mice.
  Medline CASGoogle Scholar